About Sloning BioTechnology
Sloning BioTechnology is a Healthcare company based in Puchheim (Germany) founded in 2001, and was acquired by MorphoSys in October 2010. Technology for the construction of protein libraries. Sloning BioTechnology has raised $11.86 million across 3 funding rounds from investors including MorphoSys, KfW and HBM Healthcare Investments. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Sloning Biotechnology has developed a patented technology platform to build protein libraries. Its patented Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at predetermined positions with speed. It claims that the technology opens the way to a new and flexible approach to generating optimized proteins, such as antibodies. In October 2010, it was acquired by MorphoSys.
- Headquarters Puchheim, Germany
- Stage Acquired
- SectorsHealthcare
- Website sloning.com
- Acquired by MorphoSys (Oct 2010)
Funding Insights of Sloning BioTechnology
Sloning BioTechnology has successfully raised a total of $11.86M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.86M
- Total Rounds 3
- First Round $4.91M
(May 2003)
- Investors Count 4
All 3 funding rounds of Sloning BioTechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2009 | Series E | – | HBM Healthcare Investments, KfW | – | |
| Nov 2007 | $6.95M | Series E | – | KfW, DEWB | |
| May 2003 | $4.91M | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Sloning BioTechnology
Sloning BioTechnology has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include MorphoSys, KfW and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Early-stage VC firm investing in smart & deep-tech, fin-tech and life science & health-tech sectors | lbbwvc.de | Stuttgart, Germany | ||
Investments in asset management and fintech are made by DEWB. | dewb.de | Germany | ||
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
Therapeutic antibodies for cancer and other diseases are developed. | 1992 | morphosys.com | Planegg, Germany |
Investor details for Sloning BioTechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sloning BioTechnology
4 dated milestones of Sloning BioTechnology across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sloning BioTechnology is founded.
- Funding First funding round of $4.9M.
- Funding Latest funding round, Series E,.
- Exit Acquired by MorphoSys.
Web traffic of Sloning BioTechnology
Websites that share an audience with Sloning BioTechnology (sloning.com).
Websites whose visitors overlap most with Sloning BioTechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| geneart.com | 100% | View details | |||
| celprogen.com | 100% | #3,394,353 | View details | ||
| cellcentric.com | 100% | 5.5K | #3,262,513 | View details | |
atglabs.com | atglabs.com | 100% | – | ||
| genaxxon.com | 100% | 16.5K | #1,573,860 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Sloning BioTechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sloning Biotechnology
Complete news archive for Sloning BioTechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sloning BioTechnology
Sloning BioTechnology was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Sloning BioTechnology is headquartered in Puchheim, Germany. It is registered at Puchheim, Bavaria, Germany.
Sloning BioTechnology is a funded company, having raised a total of $11.86M across 3 funding rounds to date. The company's 1st funding round was a Series B of $4.91M, raised on May 2003.
Sloning Biotechnology has developed a patented technology platform to build protein libraries. Its patented Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at predetermined positions with speed. It claims that the technology opens the way to a new and flexible approach to generating optimized proteins, such as antibodies. In October 2010, it was acquired by MorphoSys.
Sloning BioTechnology has 5 investors. Key investors include MorphoSys, KfW, HBM Healthcare Investments, LBBW Venture Capital, and DEWB.
Yes. Sloning BioTechnology was acquired by MorphoSys in October 2010.